A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
- Conditions
- Overactive Bladder (OAB)
- Interventions
- Device: solifenacinDevice: propiverine
- Registration Number
- NCT03572231
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Brief Summary
The purpose of this study is to observe and describe treatment patterns, like Overactive Bladder (OAB) treatment discontinuation, switching to other therapies and persistence of OAB therapies in routine clinical practice.
This study will also evaluate effectiveness of OAB therapies in routine clinical practice; identify factors associated with effectiveness and persistence of pharmacologic therapies in OAB participants; evaluate the Quality of Life (QoL) and treatment satisfaction of OAB therapies; as well as evaluate health care resource utilization (HCRU) and understand adverse events (AEs), serious adverse events (SAEs) and adverse drug reactions (ADRs) associated with OAB therapies.
- Detailed Description
This is an observational registry study and will not provide or recommend any treatment; all decisions regarding treatment are made at the sole discretion of the treating physician in accordance with the treating physician's usual practices and all eligible participants will be enrolled in a certain timeframe. OAB participants enrolled in the study will be categorized into one of two treatment groups, but the study does not plan to compare the two treatment groups.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 805
- Diagnosed with OAB symptoms (with or without urgency incontinence) with symptoms for at least three months prior to study enrollment.
- About to initiate monotherapy of mirabegron or any antimuscarinics therapy for OAB symptoms, prescribed as part of routine clinical practice, which maybe the first course of any treatment for OAB, lapsed of treatment, or switching from one drug to another.
- Currently receiving more than one medication (including Chinese herbal medicine) for OAB.
- Current participation in clinical trials of OAB.
- Have undergone surgery for OAB in the past.
- Mixed incontinence where stress incontinence is the predominant form.
- OAB has been treated with onabotulinum toxin A, sacral neuromodulation, percutaneous tibial nerve stimulation, external beam radiation (XRT), stents, surgery, or intermittent catheterization prior to or at time of enrollment.
- At risk of Acute Urinary Retention (AUR).
- Neurologic conditions associated with OAB symptoms.
- Hypersensitivity and contraindication(s) to mirabegron and antimuscarinics.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Antimuscarinics solifenacin Participants will commence the OAB treatment with one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine. The antimuscarinic is prescribed by a physician in routine clinical practice. Antimuscarinics propiverine Participants will commence the OAB treatment with one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine. The antimuscarinic is prescribed by a physician in routine clinical practice. mirabegron mirabegron Participants will commence the OAB treatment with mirabegron that is prescribed by a physician in routine clinical practice. Antimuscarinics imidafenacin Participants will commence the OAB treatment with one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine. The antimuscarinic is prescribed by a physician in routine clinical practice. Antimuscarinics darifenacin Participants will commence the OAB treatment with one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine. The antimuscarinic is prescribed by a physician in routine clinical practice. Antimuscarinics tolterodine Participants will commence the OAB treatment with one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine. The antimuscarinic is prescribed by a physician in routine clinical practice. Antimuscarinics trospium Participants will commence the OAB treatment with one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine. The antimuscarinic is prescribed by a physician in routine clinical practice. Antimuscarinics oxybutynin Participants will commence the OAB treatment with one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine. The antimuscarinic is prescribed by a physician in routine clinical practice. Antimuscarinics fesoterodine Participants will commence the OAB treatment with one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine. The antimuscarinic is prescribed by a physician in routine clinical practice.
- Primary Outcome Measures
Name Time Method Time from treatment initiation to discontinuation of Overactive Bladder (OAB) therapy Up to 26 weeks Discontinuation will include participants who discontinue mirabegron or antimuscarinics for more than 30 days (defined as the day after the last day of the prior supply to the next dispensing date).
Proportion of participants who discontinue OAB treatment Up to 26 weeks Discontinuation will include participants who discontinue mirabegron or antimuscarinics for more than 30 days (defined as the day after the last day of the prior supply to the next dispensing date).
Time from treatment initiation to switching to another OAB therapy or dose Up to 26 weeks Switching will be defined as a subset of initial mirabegron or antimuscarinics discontinuers who initiated another/different therapy(ies) within the follow-up period or within 30 days of being prescribed the first treatment. Change of treatment to another formulation of the same drug type under the same dosage will not be considered as switching.
Proportion of participants who switch to another treatment or dose Up to 26 weeks Switching will be defined as a subset of initial mirabegron or antimuscarinics discontinuers who initiated another/different therapy(ies) within the follow-up period or within 30 days of being prescribed the first treatment. Change of treatment to another formulation of the same drug type under the same dosage will not be considered as switching.
- Secondary Outcome Measures
Name Time Method Change from baseline in Overactive Bladder Questionnaire-Short Form (OAB-Q-SF) score Baseline, weeks 10-14 and weeks 22-26 Overactive Bladder Questionnaire-Short Form (OAB-Q-SF) is a participant-reported instrument consisting of 19 items that assess the degree to which a participant is bothered by OAB symptoms, and the degree of impact of OAB symptoms on daily life. Participants rate each item using a 6-point Likert Scale ranging from "Not at all" to "A very great deal" for the symptom bother items and "none of the time" to "All of the time" for the Health Related Quality of Life (HRQL) items.
Identify factors associated with the effectiveness and persistence of a pharmacologic therapy for an OAB participant: Medical history Baseline (up to Day 0) Medical history will be collected from participants for analysis.
Safety assessed by Serious Adverse Events (SAEs) Up to 26 weeks Adverse event (AE) is considered "serious" if the investigator or sponsor view any of the following outcomes: Death, life-threatening, persistent or significant disability/incapacity, congenital anomaly or birth defect, hospitalization, or medically important event.
Safety assessed by Adverse Drug Reaction (ADR) Up to 26 weeks An ADR is defined as any noxious and unintended response associated with the use of a drug in humans, at any dose, where a causal relationship (drug-event) is at least a reasonable possibility.
Change from baseline in Bladder Assessment Tool (BAT) score Baseline, weeks 10-14 and weeks 22-26 Bladder Assessment Tool (BAT) is a participant-reported instrument consisting of 17 questions regarding the symptoms, bothering, impacts and treatment satisfaction in the past 7 days. Scores range from 0 to 88, a reduction in BAT score indicates an improvement.
Identify factors associated with the effectiveness and persistence of a pharmacologic therapy for an OAB participant: Demographic Information Baseline (up to Day 0) Demographic information will be collected from participants for analysis.
Identify factors associated with the effectiveness and persistence of a pharmacologic therapy for an OAB participant: OAB Medical History Baseline (up to Day 0) OAB medical history will be collected from participants for analysis.
Identify factors associated with the effectiveness and persistence of a pharmacologic therapy for an OAB participant: Concomitant medication information Up to 26 weeks Concomitant medication will be collected from participants for analysis.
Identify factors associated with the effectiveness and persistence of a pharmacologic therapy for an OAB participant: Concomitant medical conditions Up to 26 weeks Participants medical history will be collected from participants for analysis.
Health Care Resource Utilization (HCRU) related to the management of OAB Up to 26 weeks Participant information will be collected by the investigator or designee via the Healthcare Resource Utilization (HCRU) Worksheet at each visit and the data will be retrieved electronically via the electronic case report form (eCRF). The HCRU worksheet consists of 7 questions related to the participants history and treatment of OAB.
Change from baseline in Overactive Bladder Symptom Scores (OABSS) score Baseline, weeks 10-14 and weeks 22-26 Overactive Bladder Symptom Scores (OABSS) is a participant-reported instrument consisting of 4 questions regarding daytime frequency, nocturia, urgency, and urgency incontinence; evaluates relevant symptoms from the participant's viewpoint. Scores range from 0 to 15 with a lower score indicating a mild presentation of overactive bladder syndrome and a higher score indicating moderate to severe presentation of overactive bladder syndrome.
Change from baseline in Treatment Satisfaction-Visual Analog Scale (TS-VAS) score Baseline, weeks 10-14 and weeks 22-26 Treatment Satisfaction-Visual Analog Scale (TS-VAS) is a quantitative instrument assessing participant improvement in participants with OAB. A score of 10 on the TS-VAS indicates complete satisfaction, whereas a positive change from baseline indicates improvement.
Identify factors associated with the effectiveness and persistence of a pharmacologic therapy for an OAB participant: History of prior drug treatment for OAB Baseline (up to Day 0) History of prior drug treatment for OAB will be collected from participants for analysis.
Safety assessed by Adverse Events (AEs) Up to 26 weeks An AE is any untoward medical occurrence in a patient or clinical study patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a product, whether or not considered related to the product. Pre-existing conditions that worsen during a study are to be reported as AEs.
Trial Locations
- Locations (15)
Site KR410008
🇰🇷Daejeon, Korea, Republic of
Site KR410009
🇰🇷Incheon, Korea, Republic of
Site KR410005
🇰🇷Kangam, Korea, Republic of
Site KR410001
🇰🇷Seoul, Korea, Republic of
Site KR410002
🇰🇷Seoul, Korea, Republic of
Site KR410003
🇰🇷Seoul, Korea, Republic of
Site KR410006
🇰🇷Seoul, Korea, Republic of
Site KR410007
🇰🇷Seoul, Korea, Republic of
Site TW158001
🇨🇳Hualien City, Taiwan
Site KR410004
🇰🇷Suwon, Korea, Republic of
Site TW158003
🇨🇳Kaohsiung City, Taiwan
Site TW158002
🇨🇳Taichung, Taiwan
Site TW158006
🇨🇳Kaohsiung, Taiwan
Site TW158004
🇨🇳Taipei, Taiwan
Site TW158005
🇨🇳Taoyuan City, Taiwan